Biotech Value (fka )

[maytepper]

$DVAX Cowen Maintains Outperform On Dynavax Following R&D Day http://www.smarteranalyst.com/2014/12/12/cowen-maintains-outperform-on-dynavax-following-rd-day/

[maytepper]

Celldex: Merck's Immune Checkpoint Inhibitor Doesn't Threat Glemba, Says Cowen http://www.smarteranalyst.com/2014/12/10/celldex-mercks-immune-checkpoint-inhibitor-doesnt-threat-glemba-says-cowen/

[maytepper]

$INCY Cowen Maintains Outperform On Incyte Following Jakafi FDA Approval For Polycythemia Vera http://www.smarteranalyst.com/2014/12/05/cowen-maintains-outperform-on-incyte-following-jakafi-fda-approval-for-polycythemia-vera/

[maytepper]

We Expect GW’s Shares To Outperform As Its Pipeline Progresses, Says Cowen http://www.smarteranalyst.com/2014/12/03/we-expect-gws-shares-to-outperform-as-its-pipeline-progresses-says-cowen/

[maytepper]

$ABBV Deutsche Bank Comments On ABBV’s Humira Following Meeting With Momenta http://www.smarteranalyst.com/2014/12/02/deutsche-bank-comments-on-abbvs-humira-following-meeting-with-momenta/

[maytepper]

$LGND Ligand Is An Attractive Financial Growth Story With Pipeline Optionality, Says Deutsche Bank http://www.smarteranalyst.com/2014/12/02/ligand-is-an-attractive-financial-growth-story-with-pipeline-optionality-says-deutsche-bank/

[maytepper]

$TGTX Roth Capital Maintains Buy On TG Therapeutics Following Initiation Of Phase I/Ib Combination Study http://www.smarteranalyst.com/2014/12/01/roth-capital-maintains-buy-on-tg-therapeutics-following-initiation-of-phase-iib-combination-study/

[maytepper]

$SRPT Roth Capital Reiterates Buy On Sarepta Therapeutics, Sees 31% Upside http://www.smarteranalyst.com/2014/12/01/roth-capital-reiterates-buy-on-sarepta-therapeutics-sees-31-upside/

[pistol1p]

RXII up 15% today.

3 phaseII trials currently underway and data should be released in the next few months.

[maytepper]

$BDSI William Blair Reiterates Outperform On Biodelivery Sciences Following Management Meetings With investors http://www.smarteranalyst.com/2014/11/26/william-blair-reiterates-outperform-on-biodelivery-sciences-following-management-meetings-with-investors/

[maytepper]

$LGND Cantor Raises Ligand Pharmaceuticals Price Target But Still Sees Downside http://www.smarteranalyst.com/2014/11/20/cantor-raises-ligand-pharmaceuticals-price-target-but-still-sees-downside/

[pistol1p]

I definitely agree that RXII is Undervalued and is a great bargain at or near $1.80 pps.

I think you have shareholders that have purchase shares and many have added at these recent prices, and are holding them tight. The volume has been low since these shareholders are holding their shares looking for more positive news from the 3 phase 2 trials currently underway.

Share price should appreciate as more positive data is released.

[maytepper]

$SRPT Roth Capital Remains Bullish On Sarepta Therapeutics, $22 PT http://www.smarteranalyst.com/2014/11/19/roth-capital-remains-bullish-on-sarepta-therapeutics-22-pt/

[maytepper]

RXi Pharmaceuticals Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright http://www.smarteranalyst.com/2014/11/18/rxi-pharmaceuticals-represents-an-undervalued-player-with-significant-upside-says-h-c-wainwright/

[maytepper]

$KERX Brean Capital Reiterates Buy on Keryx Biopharmaceuticals Following Key Opinion Leader Forum http://www.smarteranalyst.com/2014/11/18/brean-capital-reiterates-buy-on-keryx-biopharmaceuticals-following-key-opinion-leader-forum/

[maytepper]

$KERX Maxim Reiterates Buy On Keryx Following OLE 48-Week Data for Ferric Citrate http://www.smarteranalyst.com/2014/11/17/maxim-reiterates-buy-on-keryx-following-ole-48-week-data-for-ferric-citrate/

[maytepper]

$STML Roth Capital Reiterates Buy On Stemline Following 3Q14 Results http://www.smarteranalyst.com/2014/11/14/roth-capital-reiterates-buy-on-stemline-following-3q14-results/

[maytepper]

$TNXP Roth Capital Reiterates Buy On Tonix Pharmaceuticals As Risk-Reward Is Favorable http://www.smarteranalyst.com/2014/11/14/roth-capital-reiterates-buy-on-tonix-pharmaceuticals-as-risk-reward-is-favorable/

[maytepper]

Fate Therapeutics Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright http://www.smarteranalyst.com/2014/11/13/fate-therapeutics-represents-an-undervalued-player-with-significant-upside-says-h-c-wainwright/

[maytepper]

$TTPH Brean Capital Reiterates Buy On Tetraphas Shares, Sees 5% Downside http://www.smarteranalyst.com/2014/11/12/brean-capital-reiterates-buy-on-tetraphas-shares-sees-5-downside/

[maytepper]

$NEO Roth Capital Reiterates Buy On NeoGenomics Ahead Of Investor Meetings With Management http://www.smarteranalyst.com/2014/11/11/roth-capital-reiterates-buy-on-neogenomics-ahead-of-investor-meetings-with-management/

[maytepper]

$LGND $SAGE SAGE-547 SRSE Data Highlight The Advantage Of Ligand's Technology, Says Roth Capital http://www.smarteranalyst.com/2014/11/11/sage-547-srse-data-highlight-the-advantage-of-ligands-technology-says-roth-capital/

[maytepper]

$KERX Roth Capital Reiterates Buy On Keryx Following 3Q14 Results; Keeps $32 PT http://www.smarteranalyst.com/2014/11/06/roth-capital-reiterates-buy-on-keryx-following-3q14-results-keeps-32-pt/

[maytepper]

$ACUR Acura Quarterly Update; Roth Capital Reiterates Buy http://www.smarteranalyst.com/2014/11/05/acura-quarterly-update-roth-capital-reiterates-buy/

[maytepper]

$PACB William Blair Maintains Market Perform Ahead Of Third-Quarter Earnings http://www.smarteranalyst.com/2014/10/15/william-blair-maintains-market-perform-ahead-third-quarter-earnings/

[maytepper]

$DRTX Durata Therapeutics: Moving To Neutral On Likely Closure Of Actavis Takeout, Says Roth Capital http://www.smarteranalyst.com/2014/10/15/durata-therapeutics-moving-neutral-likely-closure-actavis-takeout-says-roth-capital/

[maytepper]

$PTCT Oppenheimer Provides Key Takeaways On PTC Therapeutics Following Data Presentation At WMS http://www.smarteranalyst.com/2014/10/14/oppenheimer-provides-key-takeaways-ptc-therapeutics-following-data-presentation-wms/

[maytepper]

$ATHN Oppenheimer Maintains Bearish View On Athenahealth Ahead Of 3Q14 Results http://www.smarteranalyst.com/2014/10/14/oppenheimer-maintains-bearish-view-athenahealth-ahead-3q14-results/

[maytepper]

$PCYC Roth Capital Maintains Buy On Pharmacyclics Following Clinical Collaboration http://www.smarteranalyst.com/2014/10/14/roth-capital-maintains-buy-pharmacyclics-following-clinical-collaboration/

[maytepper]

$CUR Neuralstem Shares Are Currently Fairly Valued, Says H.C. Wainwright http://www.smarteranalyst.com/2014/10/13/neuralstem-shares-currently-fairly-valued-says-h-c-wainwright/

[maytepper]

$MNTA Maxim Group Reiterates Buy On Momenta Pharmaceuticals Following R&D Day http://www.smarteranalyst.com/2014/10/13/maxim-group-reiterates-buy-momenta-pharmaceuticals-following-rd-day/

[maytepper]

$MNTA Maxim Group Maintains Buy On Momenta Following Phase 1/2 Trial Results Of Necuparanib http://www.smarteranalyst.com/2014/10/10/maxim-group-maintains-buy-momenta-following-phase-12-trial-results-necuparanib/

[maytepper]

$ARIA Ariad: We Expect Investors To Be Relieved In Light Of PRAC Review Of Iclusig Label, Says Cowen http://www.smarteranalyst.com/2014/10/10/ariad-expect-investors-relieved-light-prac-review-iclusig-label-says-cowen/

[maytepper]

$AGN Deutsche Bank Views Allergan As A Best-In-Class Specialty Pharma Company; Initiates Buy http://www.smarteranalyst.com/2014/10/09/deutsche-bank-views-allergan-best-class-specialty-pharma-company-initiates-buy/

[maytepper]

$LGND We Continue To Be Impressed By Ligand’s Revenue Growth, Says Roth Capital http://www.smarteranalyst.com/2014/10/09/continue-impressed-ligands-revenue-growth-says-roth-capital/

[maytepper]

$LGND Ligand: 3Q:14 Guidance Revision Not Likely To Rally Shares Upward, Says Cantor http://www.smarteranalyst.com/2014/10/08/ligand-3q14-guidance-revision-not-likely-to-rally-shares-upward-says-cantor/

[maytepper]

$PCRX Brean Capital Maintains Buy On Pacira Following Visit In Manufacturing Site http://www.smarteranalyst.com/2014/10/08/brean-capital-maintains-buy-on-pacira-following-visit-in-manufacturing-site/

[maytepper]

$PTCT PTC Therapeutics: EU Translarna Launch May Generate Headwinds, Says Cowen http://www.smarteranalyst.com/2014/10/06/ptc-therapeutics-eu-translarna-launch-may-generate-headwinds-says-cowen/

[maytepper]

$MDT Oppenheimer Maintains Outperform On Medtronic On The Back Of Financial Plans http://www.smarteranalyst.com/2014/10/06/oppenheimer-maintains-outperform-medtronic-back-financial-plans/

[maytepper]

$SLXP William Blair Maintains Outperform On Salix Following Cosmo Deal Cancellation http://www.smarteranalyst.com/2014/10/03/william-blair-maintains-outperform-salix-following-cosmo-deal-cancellation/

[maytepper]

$CRIS Roth Capital Reiterated Buy On Curis On The Back Of Clinical Development Update http://www.smarteranalyst.com/2014/10/03/roth-capital-reiterated-buy-curis-back-clinical-development-update/

[maytepper]

$ALIM Cowen Maintains Bullish Stance On Alimera On The Heels Of Iluvien FDA Approval http://www.smarteranalyst.com/2014/10/03/cowen-maintains-bullish-stance-alimera-heels-iluvien-fda-approval/

[maytepper]

$MACK Merrimack: Brean Capital Highlights Key Takeaways From Management Meeting http://www.smarteranalyst.com/2014/10/03/merrimack-brean-capital-highlights-key-takeaways-management-meeting/

[maytepper]

$NEPT Neptune: Phase 2 Topline Win Welcomes Neptune Into Prescription Omega-3 League, Says H.C. Wainwright http://www.smarteranalyst.com/2014/10/03/neptune-phase-2-topline-win-welcomes-neptune-prescription-omega-3-league-says-h-c-wainwright/

[maytepper]

$BIIB Biogen: Cowen Analyst Sheds Light On Eloctate’s Rejection By UNH http://www.smarteranalyst.com/2014/10/03/biogen-cowen-analyst-sheds-light-eloctates-rejection-unh/

[maytepper]

$IG $VRX Oppenheimer Reiterates Outperform On Igi Laboratories On The Heels Of A New Deal With Valeant http://www.smarteranalyst.com/2014/10/02/oppenheimer-reiterates-outperform-igi-laboratories-heels-new-deal-valeant/

[maytepper]

$ALXN Cowen Provides Update On Alexion Following Meetings With Management http://www.smarteranalyst.com/2014/10/01/cowen-provides-update-alexion-following-meetings-management/

[maytepper]

$REGN Roth Capital Reiterates Buy On Regeneron Pharmaceuticals Following Positive Trial Results http://www.smarteranalyst.com/2014/10/01/roth-capital-reiterates-buy-regeneron-pharmaceuticals-following-positive-trial-results/

[maytepper]

$CPRX Catalyst Pharmaceutical: Roth Capital Analyst Sees 85% Probability Of US Approval For Firdapse http://www.smarteranalyst.com/2014/09/30/catalyst-pharmaceutical-roth-capital-sees-85-probability-us-approval-firdapse/

[maytepper]

$KERX Maxim Raises Keryx Price Target To $26 Following Ferric Citrate Pricing http://www.smarteranalyst.com/2014/09/30/maxim-raises-keryx-price-target-26-following-ferric-citrate-pricing/